April 26, 2021

To
The Manager,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip Code - 532523

Subject: Company Statement

Dear Sir/Madam,

Please find attached a Company Statement titled “Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab.”

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

MAYANK VERMA
Company Secretary and Compliance Officer

To
The Manager,
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050

Scrip Symbol - Biocon
NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab

Bengaluru, India; April 26, 2021:

“This is to inform that Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has announced that Abevmy® 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. (NASDAQ: VTRS) has received marketing authorization approval from the European Commission following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

Abevmy® 100 & 400 mg, a biosimilar Bevacizumab, is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

“The European Commission’s approval of our biosimilar Bevacizumab will enable us to offer this biologic therapy to cancer patients in the EU along with our partner Viatris. The addition of biosimilar Bevacizumab will strengthen our portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim. This approval is an outcome of a great team effort and years of hard work and underlines our commitment to expand affordable access to life-saving biosimilars and make an enduring impact on global health.”

-- Company Spokesperson, Biocon Biologics.

For more information
seema.ahuja@biocon.com
+919972317792